- Medical - Devices
- Healthcare
-
2.45
EPS
-
25.49
P/E
-
37.6B
MARKET CAP
-
0.00%
DIV YIELD
Company Overview
ONE EDWARDS WAY,IRVINE CA 92614,9492502500
CEO
Mr. Bernard J. Zovighian
Employess
19800
Sector
Healthcare
Industry
Medical - Devices
Website
https://www.edwards.com
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Next Earnings Date
Oct. 23, 2024
Ex Dividends date
--
Dividend Date
--
YTD Performance
-17.47%
Fiscal Year End
12-31
IPO Date
2000-03-27
Growth Rates
(avg. rate of change) | 10 years | 5 years | 3 years | 1 year |
---|---|---|---|---|
Sales/Revenue | 11.37% | 10.03% | 11.04% | 11.56% |
EPS | 14.62% | 14.97% | 20.51% | -6.10% |
Equity | 15.61% | 16.19% | 13.28% | 14.52% |
Cash | 10.53% | 9.88% | -1.12% | 48.76% |
Return On Capital (ROIC) | 18.94% | 21.76% | 19.90% | 18.29% |
Debt
year (millions) | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Short Term Debt | 24.9 | 25.5 | 25.5 | 27.2 | 25.5 |
Long Term Debt | 670 | 666 | 665 | 668 | 653 |
LT Finance Leases | 97.9 | 95 | 94.6 | 99.9 | 84.4 |
Shares Outstanding | 607 | 619 | 623 | 623 | 625 |
Market Cap | 46,300 | 46,200 | 80,700 | 56,800 | 48,600 |
Price
News
An Investigation Has Commenced on Behalf of Edwards Lifesciences Corporation Shareholders. Contact Levi & Korsinsky to Discuss your EW Losses.
2 monthsNEW YORK, NY / ACCESSWIRE / July 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edwards Lifesciences Corporation ("Edwards Lifesciences") (NYSE:EW) concerning possible violations of federal securities laws. On October 28, 2022, Edwards announced 3Q 2022 financial results that missed revenue estimates and then lowered revenue guidance for the 4Q.
accesswire.com3 Healthcare Stocks to Buy at a 52-Week Low in July
2 monthsFinding value in this market is difficult because the S&P 500 has increased over 50% since its bottom in October 2022. Certainly, you won't find it in technology or mega caps, which have soared due to the AI craze.
investorplace.comEdwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
2 monthsEdwards Lifesciences cut TAVR guidance, stock price dropped by over 31%. Recent acquisitions and divestiture of the Critical Care business show strategic focus on the structural heart market. Analyst reiterates 'Strong Buy' rating with a fair value of $72 per share, confident in long-term growth potential.
seekingalpha.comLevi & Korsinsky Investigates Possible Securities Fraud Violations by Edwards Lifesciences Corporation (EW)
2 monthsNEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edwards Lifesciences Corporation ("Edwards Lifesciences") (NYSE:EW) concerning possible violations of federal securities laws. On October 28, 2022, Edwards announced 3Q 2022 financial results that missed revenue estimates and then lowered revenue guidance for the 4Q.
accesswire.comS&P 500 Gains and Losses Today: Edwards Lifesciences Sinks on Outlook for Key Product
2 monthsMajor U.S. equities indexes were mixed after a report showing U.S. gross domestic product (GDP) grew at a greater-than-expected annualized rate of 2.8% in the second quarter.
investopedia.comEdwards Lifesciences Stock Plummeted Today. Here's Why
2 monthsEdwards Lifesciences (EW) shares swooned Thursday, dropping after the company damped expectations for heart valve replacement sales growth on Wednesday.
investopedia.comEdwards Lifesciences Stock Tumbles, Highlights Slowdown In TAVR Business
2 monthsEdwards Lifesciences Corp EW reported Wednesday second-quarter adjusted EPS of 70 cents, beating the consensus of 69 cents.
benzinga.comThese Analysts Slash Their Forecasts On Edwards Lifesciences Following Q2 Results
2 monthsEdwards Lifesciences Corporation EW reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix.
benzinga.comEdwards Lifesciences (EW) Q2 Earnings Meet Mark, Margins Crash
2 monthsEdwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.
zacks.comWhy Is Edwards Lifesciences (EW) Stock Down 22% Today?
2 monthsEdwards Lifesciences (NYSE: EW ) stock is down on Thursday after the heart disease care company announced earnings for its second quarter of 2024. That earnings report starts with its adjusted EPS of 70 cents.
investorplace.comPeijia Medical's Licensing Partner, JenaValve Technology, Inc., is Expected to be Acquired by Edwards Lifesciences
2 monthsPeijia to maintain exclusive rights in Greater China to commercialize JenaValve's Trilogy Transcatheter Heart Valve (THV) System SUZHOU, China , July 25, 2024 /PRNewswire/ -- Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, today commented on the expected acquisition of JenaValve Technology, Inc. ("JenaValve"), an exclusive technology licensing partner of Peijia, by Edwards Lifesciences ("Edwards"). On July 24, 2024, Edwards announced that it had entered into an agreement to acquire JenaValve, a pioneer in the transcatheter treatment of aortic regurgitation (AR), a deadly disease that impacts a significant and growing population and is currently untreated today.
prnewswire.comEdwards Lifesciences Stock Plunges 24% After Earnings. What Wall Street Thinks.
2 monthsThe medical-technologies company misses second-quarter sales estimates.
barrons.com